aDivision of Antimicrobial Resistance, Korea National Institute of Health, Osong, Korea
bDepartment of Laboratory Medicine, Ewha Womans University School of Medicine, Seoul, Korea
cDepartment of Internal Medicine, Daejeon St. Mary's Hospital, Daejeon, Korea
© 2013 Published by Elsevier B.V. on behalf of Korea Centers for Disease Control and Prevention.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The percentages refer to the percentage of patients within each Staphylococcus aureus subset with the indicated virulence gene.
*The p values comparing the values for the two groups were determined using a two-sided Fisher's exact test (p < 0.05). As determined by the Fisher exact test; all p values shown in this table (referring to a comparison of values for biofilm-forming and non-forming isolates) are statistically significant with a false discovery rate of < 20%.
Antibiotic resistance profiles | No. of isolates | % | |
---|---|---|---|
Biofilm formers (86) | OX-P | 12/86 | 13.9 |
OX-P-CLI | 4/86 | 4.7 | |
OX-P-TET | 1/86 | 1.2 | |
OX-P-CIP-CLI | 7/86 | 8.1 | |
OX-P-CLI-TET | 1/86 | 1.2 | |
OX-P-CIP-TET | 1/86 | 1.2 | |
OX-P-CIP-CLI-SXT | 1/86 | 1.2 | |
OX-P-CIP-CLI-TET | 57/86 | 66.2 | |
OX-P-CIP-CLI-TET-SXT | 1/86 | 1.2 | |
Biofilm non-formers (40) | OX-P | 17/40 | 42.5 |
OX-P-CIP | 1/40 | 2.5 | |
OX-P-TET | 1/40 | 2.5 | |
OX-P-CIP-CLI | 3/40 | 7.5 | |
OX-P-CIP-CLI-TET | 17/40 | 42.5 | |
OX-P-CIP-CLI-TET-SXT | 1/40 | 2.5 |
Characteristic | No. (%) of MRSA isolates | p∗ | |
---|---|---|---|
Biofilm formers (n = 86) | Biofilm non-formers (n = 40) | ||
agr group | |||
I | 25 (29.1) | 18 (45.0) | 0.357 |
II | 55 (64.0) | 20 (50.0) | |
III | 3 (3.5) | 1 (2.5) | |
SCCmec type | |||
I | 0 (0.0) | 0 (0.0) | 0.055 |
II | 60 (69.8) | 20 (50.0) | |
III | 6 (7.0) | 1 (2.5) | |
IV | 18 (20.9) | 18 (45.0) | |
MLST | |||
ST1 | 2 (2.3) | 1 (2.5) | |
ST5 | 60 (69.8) | 21 (52.5) | 0.060 |
ST8 | 1 (1.2) | 0 (0.0) | |
ST72 | 16 (18.6) | 17 (42.5) | 0.005 |
ST239 | 7 (8.1) | 1 (2.5) | 0.434 |
Functional category | No. of isolates by biofilm formation (%); | ||
---|---|---|---|
Positive, n = 86 | Negative, n = 40 | p∗ | |
Adhesin-encoding genes | |||
icaA | 83 (96.5) | 38 (95.0) | 0.652 |
icaD | 86 (100) | 40 (100) | |
cna | 80 (93.0) | 36 (90.0) | 0.724 |
atl | 86 (100) | 40 (100) | |
fnbA | 83 (96.5) | 39 (97.5) | 1.000 |
fnbB | 64 (74.4) | 18 (45.0) | 0.001 |
Toxin-encoding genes | |||
SEs | 86 (100) | 40 (100) | |
eta, etb, etd | 1 (1.2) | 0 (0.0) | 1.000 |
tst | 78 (90.7) | 34 (39.5) | 0.370 |
PVL | 2 (2.3) | 0 (0.0) | 1.000 |
hla | 83 (96.5) | 38 (95.0) | 0.652 |
hlb | 86 (100) | 39 (97.5) | 0.317 |
Surface-associated genes | |||
cap5HK | 75 (87.2) | 35 (87.5) | 0.964 |
cap8HK | 9 (10.5) | 3 (7.5) | 0.751 |
Staphylococcal regulators | |||
sarA | 86 (100) | 40 (100) | |
arlRS | 80 (93.0) | 39 (97.5) | 0.430 |
Characteristics | Biofilm formers n (%) | Bioflim non-formers n (%) | p | OR (CI95) |
---|---|---|---|---|
Age, years | 0.203 | 0.985 (0.964–1.008) | ||
Mean ± SD | 63.8 ± 12.5 | 56.7 ± 14.7 | ||
Median (range) | 69 (1–98) | 65 (1–80) | ||
Male:female | 56:30 | 26:14 | 0.990 | |
MRSA isolates | ||||
Onset of infection | ||||
Nosocomial | 67 (77.9) | 24 (60.0) | 0.024 | 2.434 (1.111–5.331) |
Community onset | 19 (22.1) | 16 (40.0) | ||
Site of infection | ||||
Endocarditis | 2 (2.3) | 0 (0) | 0.255 | |
Lung infection | 7 (8.1) | 5 (12.5) | 0.407 | |
SSTI/Bone | 8 (9.3) | 3 (7.5) | 0.857 | |
CRI | 31 (36.0) | 21 (52.5) | 0.466 | |
Other sites | 3 (3.5) | 0 (0) | 0.281 | |
Primary | 33 (38.4) | 14 (35.0) | 0.629 | |
Clinical outcome | ||||
Crude mortality | 29 (37.7) | 16 (40.0) | 0.423 | |
MRSA-related death | 16 (18.6) | 6 (15.0) | 0.203 | |
Eradication of MRSA | 0.824 | |||
Success | 56 (72.7) | 26 (65.0) | ||
Failure | 19 (22.1) | 10 (25.0) |
Healthcare-associated risk factors | Biofilm formers (%) | Biofilm non-formers (%) | p | Odds ratio (95% confidence interval) |
---|---|---|---|---|
Presence of invasive device | 85.7 | 61.2 | 0.002 | 3.87 (1.60–8.96) |
Prior antibiotic use | 71.6 | 62.5 | 0.535 | 1.37 (0.49–3.89) |
Residence in LTCF | 12.5 | 10.0 | 0.704 | 1.30 (0.33–5.12) |
Prior hospitalization | 60.2 | 40.0 | 0.024 | 0.40 (0.18–0.88) |
Prior surgery | 36.4 | 17.5 | 0.121 | 0.47 (0.17–1.22) |
Receipt of hemodialysis | 26.1 | 30.0 | 0.278 | 1.65 (0.66–4.09) |
Prior MRSA colonization | 33.8 | 15.0 | 0.295 | 0.61 (0.24–1.54) |
CIP = ciprofloxacin; CLI = clindamycin; OX = oxacillin; P = penicillin; SXT = trimethoprim-sulfamethoxazole; TET = tetracycline.
*The MLST = multilocus sequence typing; MRSA = methicillin-resistant
The percentages refer to the percentage of patients within each *The
CI95 = 95% confidence interval; CRI = catheter-related infection; MRSA = methicillin-resistant
LTCF = long-term care facility.